IS ONGOING FOR APPROVAL
therapy has been realized with genetic technologies.
THINK TANK COMPANY
the health of those we serve.
TO NEW HEALTH SOLUTIONS
It´s their goal realizing best medical solutions.
Pharmact
OUR MISSION
At Pharmact, our mission is to improve the health of those we serve. We have focused on the most important clinical pictures, arteriosclerosis and diabetes.
.
Pharmact
INTERNATIONAL
We work worldwide with pharmaceutical wholeseller and distributions. We are pleased if you would like being part of our network.
.
Pharmact
MEDICAL DEVICES
Our IVD rapid test products are excellent for the screening of metabolic diseases and risk diagnosis. Take advantage of our Smart Devices.
.
NEWS PRODUCTS
SARS-CoV-2 Antibody testing
If being infected with SARS-CoV, you can check your actual status. The infection is recognized by the immunoglobulins IgM and IgG in the blood of patients. When cross-matched with the PCR smear test, our test shows 99,8% correlation in the detection of non-infected persons.
By 20 June 2020, a cumulative amount of 1,809 tests had been carried out for validation. Of those, 643 measurements were evaluated to determine test sensitivity and 1,166 to determine specificity.The Point-of-Care test may be ordered by healthcare professionals and pharmacies only. More…
Screening for metabolic diseases on early stages
The effective therapy of diabetes mellitus and arteriosclerosis as well as their sequelae is one of the greatest medical challenges of our time. More…
NEW PROJECTS
SARS-CoV-2, Antigen test in 5 minutes.
We have developed “BELMONITOR CoV-2” to provide the fastest test time for the specific detection of a SARS-CoV-2 infection during the infectious phase. The rapid fluorescence test rapidly identifies specific proteins and/or components of the SARS-CoV-2 virus. The test will be offered as a professional application for mass screening and soon for in-house use. Preliminary performance data are:
-
- Specificity > 99.0 %
- Sensitivity > 98.0%
- Accuracy > 98.0%
New substance in registration process
Arteriosclerosis is a silent disease that partially leads to calcifying hardening of the arterial system. Pharmact has developed a specific drug that is available from the beginning of Q2. 2020. The substance has now been entered the drug approval process.
Interested in more?
Ask our partners!
DISTRIBUTION
EUROPE
Pharmact GmbH
Int´l Distribution
Headquarters
Phone: +49 621-1806178-0
E-Mail: sales@pharmact.de
NORTH AMERICA
Pharmact Healthcare Inc.
Distribution
USA / CAN
Phone: +1 813 200 5884
E-Mail:
sales@pharmact-us.com
ASEAN
Pharmact Health Ltd.
Distribution
Malaysia
Phone: +6 03 2181 2111
E-Mail:
sales@pharmact-health.asia
PARTNER
BBL Healthcare Solutions Ltd.
Distribution
Agency UK
Phone: +44 7848 844 048
E-Mail:
info@bblhealthcaresolutions.com